The application of the biological agents in certain aggressive types of ocular inflammation, such as Behcet's disease, represents a main topic in uveitis treatment. Adalimumab has shown a more comparable efficacy than infliximab in Behcet's disease, offering a better patient compliance due to the SQ administration. On the other hand, the limited number of trials available is limiting the use of adalimumab to those cases, which are not responding to the standard of care.An important issue for the biological agents is represented by the pediatric use: the drugs seems to be better tolerated by children and did not show significant side effects during the treatment.